International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control
|
|
- Colin Harris
- 6 years ago
- Views:
Transcription
1 Special Report International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control Elizabeth Fair, Philip C Hopewell and Madhukar Pai CONTENTS Tuberculosis remains a global challenge International Standards for Tuberculosis Care Differing contexts, similar challenges, a shared approach Information resources Key issues References Affiliations Tuberculosis (TB) remains an enormous global health problem. There are 8 9 million new cases and 2 million deaths from TB annually. Despite the overwhelming burden of disease, the basic principles of care for persons with, or suspected of having, TB are the same worldwide: a diagnosis should be established promptly and accurately, standardized treatment regimens of proven efficacy should be used together with appropriate treatment support and supervision, the response to treatment should be monitored, and the essential public health responsibilities must be carried out. As an approach to improving the care of patients with TB, an evidence-based document, the International Standards for Tuberculosis Care (ISTC) was developed and has been endorsed by more than 30 international and national agencies. This special report introduces the ISTC and discusses the fact that accurate diagnosis and effective treatment are not only essential for good patient care, they are the key elements in the public health response to TB and are the cornerstone of TB control. With the recent emergence of extensively drug-resistant TB, there is an urgent need to ensure globally that standards of TB care are based on rigorous scientific findings, are clear and well understood, and are accessible to and applied by all types of healthcare providers in all corners of the world. Author for correspondence McGill University, Department of Epidemiology, Biostatistics and Occupational Health, 1020 Pine Avenue West, Montreal, Quebec, H3A 1A2, Canada Tel.: Fax: madhukar.pai@mcgill.ca KEYWORDS guidelines, recommendations, standards, tuberculosis Expert Rev. Anti Infect. Ther. 5(1), (2007) Tuberculosis remains a global challenge Although in the past 10 years there has been substantial progress in the development and implementation of the strategies necessary for effective tuberculosis control, the disease remains an enormous and growing global health problem [1 4]. A third of the world s population is infected with Mycobacterium tuberculosis, with 95% of cases occuring in developing countries [3]. In 2003, there were an estimated 8.8 million new cases of tuberculosis, of which 3.9 million were sputum smearpositive and, thus, highly infectious [1,2]. The number of tuberculosis cases that occur in the world each year is still growing, although the rate of increase is slowing. In the African region of the WHO, the tuberculosis case rate continues to increase, owing to both the epidemic of HIV infection in sub-saharan countries and the poor or absent primary-care services throughout the region [1,2]. In many other countries, owing to incomplete application of effective care and control measures, tuberculosis case rates are either stagnant or decreasing more slowly than expected. The failure to bring about a more rapid reduction in tuberculosis incidence is related, at least in part, to a failure to fully engage all medical care providers in the delivery of high-quality care, in coordination with local and national tuberculosis control programs. In many parts of the world, private practitioners are involved in the diagnosis and treatment of tuberculosis [5 8]. Traditional healers, general, specialist and academic physicians, nurses, unlicensed practitioners, physicians in private practice, practitioners of alternative medicine and community organizations, / Future Drugs Ltd ISSN
2 Fair, Hopewell & Pai among others, all play roles in tuberculosis care and, therefore, in tuberculosis control. Little is known regarding the adequacy of care delivered by private providers; however, available data suggest that, in many instances, the services are of poor quality. A global situation assessment reported by the WHO, as well as other studies conducted during the past years, demonstrates that clinicians who work in the private healthcare sector often deviate from standard, internationally recommended tuberculosis management practices [6,7]. These deviations include: under-utilization of sputum microscopy for diagnosis, generally associated with over-reliance on radiography; use of nonrecommended drug regimens, with incorrect combinations of drugs and mistakes in both drug dosage and duration of treatment; and failure to supervise and assure adherence to treatment [6,7,9 15]. Anecdotal evidence also suggests that there is an over-reliance on poorly validated or inappropriate diagnostic tests, such as serological assays, often in preference to conventional bacteriological evaluations. Together, these findings highlight flaws in healthcare practices that lead to substandard tuberculosis care for populations that are most vulnerable to the disease and are least able to bear the consequences of such systemic failures. International Standards for Tuberculosis Care The basic principles of care for individuals with, or suspected of having, tuberculosis are the same worldwide: a diagnosis should be established promptly and accurately; standardized treatment regimens of proven efficacy should be used, together with appropriate treatment support and supervision; the response to treatment should be monitored; and the essential public health responsibilities must be carried out. Accurate diagnosis and effective treatment are not only essential for good patient care, they are the key elements in the public health response to tuberculosis and are the cornerstone of tuberculosis control. Substandard care will result in poor patient outcomes, continued infectiousness with transmission of M. tuberculosis to others and generation and propagation of drug resistance. As an approach to improving the care of patients with tuberculosis, the principles noted above were used as the foundation for a set of evidence-based standards, the International Standards for Tuberculosis Care (ISTC), which was released on World TB Day 2006 [16] and subsequently published in a condensed form in Lancet Infectious Diseases [17]. Since its release, the ISTC has been endorsed by more than 30 international and national agencies and organizations, including the WHO, the Stop TB Partnership, the International Union against TB and Lung Disease (IUATLD), the American Thoracic Society (ATS), the CDC, the International Council of Nurses, the Canadian Tuberculosis Committee and the World Care Council. The ISTC was developed by examining existing evidence and, where evidence was lacking, conducting rigorous systematic reviews. The result was agreement on a group of 17 standards: six addressing diagnosis, nine addressing treatment and two addressing public health responsibilities (TABLE 1). The ISTC as a whole is not meant to be a guidance document for how tuberculosis care should be provided but rather the principles and foundation on which guidelines can be based. The document emphasizes that any clinician who provides services for tuberculosis is assuming an important public health function. Differing contexts, similar challenges, a shared approach There is a vast spectrum of diagnostic, treatment and public health practices involved in tuberculosis care. The ISTC presents the essential elements of tuberculosis care and, consequently, should be viewed as a platform on which additional elements of care can be based. In many geographical areas, the available facilities and resources exceed those required to comply with the ISTC. However, even in these areas, certain elements of the standards may not be implemented. This is particularly true with regards to treatment supervision and the application of a true patient-centered approach, as specified in the ISTC. Conversely, healthcare providers from settings in which there is no regular access to vital services, such as chest radiographic examinations or drug-sensitivity testing, will recognize that they are far from able to achieve the practices recommended in the ISTC. For example, in a rural clinic in Tanzania, basic diagnostic techniques, such as sputum smear microscopy, may be a challenge owing to lack of a microscope, lack of stain or slides, or lack of electricity. In the context of such diversity, the ISTC can function as a template or checklist against which providers and programs can assess the realities of their particular situations and determine what is needed to bring practices up to the level of those specified by the ISTC. In both areas with adequate resources and in resource-constrained settings, the ISTC provides a starting point to determine what is needed a tool for a situational analysis that can then be used to guide pursuit of improved tuberculosis care. Using this standardized situational analysis as a point of departure, specific plans can be developed that, for example, may be focused on increasing funding, developing new systems or altering approaches so as to be consistent with the ISTC, with the goal of providing high-quality tuberculosis care that meets the needs of all patients. In the last few months, a new threat has been identified: extensively drug-resistant tuberculosis (XDR-TB) [18]. Currently, the WHO defines XDR-TB as tuberculosis resistant to at least rifampicin and isoniazid from among the first-line antituberculosis drugs (which is the definition of multidrug resistant [MDR]-TB) in addition to any fluoroquinolones, and to at least one of three injectable second-line antituberculosis drugs used in tuberculosis treatment (capreomycin, kanamicin and amikacin). What is evident is that had care of the quality specified in the ISTC been applied in the areas where XDR-TB is emerging, this disaster would not have happened. The emergence of XDR-TB is a sign that proper standards of tuberculosis care are far from being applied universally [19]. It is worth looking back at what the tuberculosis community learned from the experience of New York City (NY, USA) just over 10 years ago. In the early 1990s, there was a significant 62 Expert Rev. Anti Infect. Ther. 5(1), (2007)
3 International Standards for Tuberculosis Care Table 1. International Standards for Tuberculosis Care. Standards for diagnosis Standard 1 All persons with otherwise unexplained productive cough lasting 2 3 weeks should be evaluated for TB Standard 2 Standard 3 Standard 4 Standard 5 Standard 6 All patients (adults, adolescents and children who are capable of producing sputum) suspected of having pulmonary TB should have at least two, and preferably three, sputum specimens obtained for microscopic examination. When possible, at least one early morning specimen should be obtained For all patients (adults, adolescents and children) suspected of having extrapulmonary TB, appropriate specimens from the suspected sites of involvement should be obtained for microscopy and, where facilities and resources are available, for culture and histopathological examination All persons with chest radiographical findings suggestive of TB should have sputum specimens submitted for microbiological examination The diagnosis of sputum smear-negative pulmonary TB should be based on the following criteria: at least three negative sputum smears (including at least one early morning specimen); chest radiography findings consistent with TB; and lack of response to a trial of broad-spectrum antimicrobial agents. (Since fluoroquinolones are active against Mycobacterium tuberculosis complex and, thus, may cause transient improvement in persons with TB, they should be avoided). For such patients, if facilities are available, sputum cultures should be obtained. In individuals with known or suspected HIV infection, the diagnostic evaluation should be expedited The diagnosis of intrathoracic (i.e., pulmonary, pleural and mediastinal or hilar lymph node) TB in symptomatic children with negative sputum smears should be based on the finding of chest radiographical abnormalities consistent with TB and either a history of exposure to an infectious case or evidence of TB infection (positive tuberculin skin test or interferon-γ release assay). For such patients, if facilities for culture are available, sputum specimens should be obtained (by expectoration, gastric washings or induced sputum) for culture Standards for treatment Standard 7 Any practitioner treating a patient for TB is assuming an important public health responsibility. To fulfill this responsibility, the practitioner must not only prescribe an appropriate regimen, but also be capable of assessing the adherence of the patient to the regimen and addressing poor adherence when it occurs. By so doing, the provider will be able to ensure adherence to the regimen until treatment is completed Standard 8 Standard 9 Standard 10 Standard 11 All patients (including those with HIV infection) who have not been treated previously should receive an internationally accepted first-line treatment regimen using drugs of known bioavailability. The initial phase should consist of 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol. The preferred continuation phase consists of isoniazid and rifampicin administered for 4 months. Isoniazid and ethambutol administered for 6 months is an alternative continuation-phase regimen that may be used when adherence cannot be assessed, but it is associated with a higher rate of failure and relapse, especially in patients with HIV infection. The doses of anti-tb drugs used should conform to international recommendations. Fixed dose combinations of two (isoniazid and rifampicin), three (isoniazid, rifampicin and pyrazinamide) and four (isoniazid, rifampicin, pyrazinamide and ethambutol) drugs are highly recommended, especially when medication ingestion is not observed To foster and assess adherence, a patient-centered approach to the administration of drug treatment, based on the patient s needs and mutual respect between the patient and the provider, should be developed for all patients. Supervision and support should be sex sensitive and age specific and should draw on the full range of recommended interventions and available support services, including patient counseling and education. A central element of the patient-centered strategy is the use of measures to assess and promote adherence to the treatment regimen and to address poor adherence when it occurs. These measures should be tailored to the individual patient s circumstances and be mutually acceptable to the patient and the provider. Such measures may include direct observation of medication ingestion (DOT) by a treatment supporter who is acceptable and accountable to the patient and the health system All patients should be monitored for response to therapy, best judged in patients with pulmonary TB by follow-up sputum microscopy (two specimens) at least at the time of completion of the initial phase of treatment (2 months), at 5 months and at the end of treatment. Patients who have positive smears during the 5th month of treatment should be considered as treatment failures and have therapy modified appropriately (see standards 14 and 15). In patients with extrapulmonary TB and in children, the response to treatment is best assessed clinically. Follow-up radiographical examinations are usually unnecessary and may be misleading A written record of all medications given, bacteriological response and adverse reactions should be maintained for all patients Taken from [16,17]. DOT: Directly observed therapy; MDR: Multidrug resistant; TB: Tuberculosis. 63
4 Fair, Hopewell & Pai Table 1. International Standards for Tuberculosis Care (cont.). Standard 12 Standard 13 Standard 14 Standard 15 In areas with a high prevalence of HIV infection in the general population and where TB and HIV infection are likely to coexist, HIV counseling and testing are indicated for all TB patients as part of their routine management. In areas with lower prevalence rates of HIV, HIV counseling and testing are indicated for TB patients with symptoms and/or signs of HIV-related conditions and in TB patients with a history suggestive of high risk of HIV exposure All patients with TB and HIV infection should be evaluated to determine whether antiretroviral therapy is indicated during the course of treatment for TB. Appropriate arrangements for access to antiretroviral drugs should be made for patients who meet indications for treatment. Given the complexity of co-administration of anti-tb treatment and antiretroviral therapy, consultation with a physician who is expert in this area is recommended before initiation of concurrent treatment for tuberculosis and HIV infection, regardless of which disease appeared first. However, initiation of treatment for TB should not be delayed. Patients with TB and HIV infection should also receive cotrimoxazole as prophylaxis for other infections An assessment of the likelihood of drug resistance, based on history of prior treatment, exposure to a possible source case having drug-resistant organisms, and the community prevalence of drug resistance should be obtained for all patients. Patients who fail treatment and chronic cases should always be assessed for possible drug resistance. For patients in whom drug resistance is considered to be likely, culture and drug susceptibility testing for isoniazid, rifampicin and ethambutol should be performed promptly Patients with TB caused by drug-resistant (especially MDR) organisms should be treated with specialized regimens containing second line anti-tb drugs. At least four drugs to which the organisms are known or presumed to be susceptible should be used and treatment should be given for 18 months. Patient-centered measures are required to ensure adherence. Consultation with a provider experienced in treatment of patients with MDR-TB should be obtained Standards for public health responsibilities Standard 16 All providers of care for patients with TB should ensure that individuals (especially children aged <5 years and individuals with HIV infection) who are in close contact with patients who have infectious TB are evaluated and managed in line with international recommendations. Children aged below 5 years and individuals with HIV infection who have been in contact with an infectious case should be evaluated for both latent infection with M. tuberculosis and for active TB Standard 17 All providers must report both new and retreatment TB cases and their treatment outcomes to local public health authorities, in conformance with applicable legal requirements and policies Taken from [16,17]. DOT: Directly observed therapy; MDR: Multidrug resistant; TB: Tuberculosis. resurgence of tuberculosis and the emergence of a highly resistant MDR-TB strain (the W strain) of M. tuberculosis in New York City. As the incidence of tuberculosis had declined over the years, so had the investment in the programs that controlled the disease. This gradual divestment in public health, coupled with the HIV epidemic, led to a resurgence of tuberculosis. By 1992, the number of cases had nearly tripled in 15 years [20]. In the first quarter of 1991, New York City, comprising only 3% of the nation s population, accounted for 61% of the MDR-TB cases in the USA [21]. In some neighborhoods of the city, incidence rates were estimated to be 222 per 100,000, greater than in many developing countries [22]. When these trends were identified, there was great alarm in the public health community and attention was refocused on the basic standards of care for tuberculosis. Within 2 years, there was a dramatic decrease in the disease. Incidence rates were cut by 20%, and there was interruption of ongoing transmission of tuberculosis. Simple programmatic interventions and planning, such as directly observed therapy, improved case detection and infection control, and broader use of drug susceptibility testing were identified as having contributed to reversing the trend. The costs borne by the public health system in New York City were extraordinary, yet the primary interventions relatively simple. Many of these interventions are the tenets of the ISTC. As we face this new threat of XDR-TB, it is imperative to revisit the cornerstones of tuberculosis care. Without diligent attention, we may see further spread of XDR-TB and this will become a serious challenge to health systems, regardless of the setting and resources. Now more than ever, we need to ensure globally that our standards of care are based on rigorous scientific findings, are clear and well understood, and are accessible to and applied by all types of health care providers public, private, certified and nontraditional in all corners of the world. Ultimately, new drugs and new diagnostics are needed, but while these work their way through the pipeline it is imperative to universally implement the essential standards of tuberculosis care. Information resources The International Standards for Tuberculosis Care report can be freely downloaded from several websites: Stop TB report.pdf The WHO The abbreviated publication [17] can be downloaded freely from the Lancet website 64 Expert Rev. Anti Infect. Ther. 5(1), (2007)
5 International Standards for Tuberculosis Care Key issues The basic principles of care for individuals with, or suspected of having, tuberculosis (TB) are the same worldwide. Accurate diagnosis and effective treatment of TB are essential for good patient care, and are key elements in the public health response to and control of TB. Incomplete and/or inadequate TB care poses a threat to the continued spread of the disease and the propagation of drug-resistant TB. There is considerable evidence that quality of TB care varies widely, and substandard care is widespread, especially in the private healthcare sector in many developing countries. As an approach to engaging all healthcare providers, and improving the care of patients with TB, a set of evidence-based standards, the International Standards for Tuberculosis Care (ISTC), were developed and released on World TB Day To improve the quality of TB care, the ISTC should be understandable, accessible and universally applied by all care providers public, private, certified and nontraditional. References 1 WHO, Global Tuberculosis Control. Surveillance, planning, financing. WHO Report. WHO, Geneva, (2005). 2 Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163(9), (2003). 3 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7), (1999). 4 Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293(22), (2005). 5 Uplekar M. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis (Edinb.) 83(1 3), (2003). 6 Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet 358(9285), (2001). 7 WHO. Involving private practitioners in tuberculosis control: issues, interventions, and emerging policy framework. WHO, Geneva, Switzerland 1 81 (2001). 8 WHO. Public-private mix for DOTS. Practical tools to help implementation. WHO, Geneva, Switzerland (2003). 9 Lonnroth K, Thuong LM, Linh PD, Diwan VK. Delay and discontinuity a survey of TB patients search of a diagnosis in a diversified health care system. Int. J. Tuberc. Lung Dis. 3(11), (1999). 10 Olle-Goig JE, Cullity JE, Vargas R. A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city. Int. J. Tuberc. Lung Dis. 3(1), (1999). 11 Prasad R, Nautiyal RG, Mukherji PK, Jain A, Singh K, Ahuja RC.. Diagnostic evaluation of pulmonary tuberculosis: what do doctors of modern medicine do in India? Int. J. Tuberc. Lung Dis. 7(1), (2003). 12 Shah SK, Sadiq H, Khalil M et al. Do private doctors follow national guidelines for managing pulmonary tuberculosis in Pakistan? East Mediterr. Health J. 9(4), (2003). 13 Singla N, Sharma PP, Singla R, Jain RC. Survey of knowledge, attitudes and practices for tuberculosis among general practitioners in Delhi, India. Int. J. Tuberc. Lung Dis.. 2(5), (1998). 14 Suleiman BA, Houssein AI, Mehta F, Hinderaker SG. Do doctors in north-western Somalia follow the national guidelines for tuberculosis management? East Mediterr. Health J. 9(4), (2003). 15 Uplekar MW Shepard DS. Treatment of tuberculosis by private general practitioners in India. Tubercle 72(4), (1991). 16 International Standards for Tuberculosis Care (ISTC). Tuberculosis Coalition for Technical Assistance, The Hague, Holland (2006). 17 Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect. Dis. 6(11), (2006). 18 Raviglione M. XDR-TB: entering the postantibiotic era? Int. J. Tuberc. Lung Dis.. 10(11), (2006). 19 The tuberculosis X factor. Lancet Infect. Dis. 6(11), 679 (2006). 20 Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City turning the tide. N. Engl. J. Med. 333(4), (1995). 21 Bloch AB, Cauthen GM, Onorato IM et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271(9), (1994). 22 Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during Bull. World Health Organ. 72(2), (1994). Affiliations Elizabeth Fair, PhD, MPH University of California, Francis J Curry National Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA Tel.: Fax: efair@globalhealth.ucsf.edu Philip C Hopewell, MD University of California, Francis J Curry National Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA Tel.: Fax: phopewell@medsfgh.ucsf.edu Madhukar Pai, MD, PhD Assistant Professor, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, 1020 Pine Avenue West, Montreal, Quebec, H3A 1A2, Canada Tel.: Fax: madhukar.pai@mcgill.ca 65
11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationThe European Union standards for tuberculosis care: do they need an update?
EDITORIAL EU STANDARDS FOR TB CARE The European Union standards for tuberculosis care: do they need an update? Marieke J. van der Werf 1, Andreas Sandgren 1, Lia D Ambrosio 2, Francesco Blasi 3 and Giovanni
More informationGuidelines for TB contact tracing in Pacific Island countries and territories
Guidelines for TB contact tracing in Pacific Island countries and territories Background Tuberculosis (TB) continues to be a public health issue of major significance around the world. The World Health
More informationDRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION
JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationRole of RNTCP in the management MDR-TB
Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationResponse to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.
Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria. Yusuf Mohammed, Mukhtar Dauda, Ifeanyi Oyeyi TB/HIV Unit, International
More informationMultidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area
Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationGUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION
GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION Agency/Organization Name of the Guide/Statement Available at World Health Organization 1
More informationIMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE
Original Article IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE P. G. Gopi, R. Subramani, V. Chandrasekaran, T. Santha and P. R. Narayanan
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationIntensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite
Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.
More informationResearch Article. The Epidemiological findings of a 5-Year study on Tuberculosis in the Khuzestan Province during 2008 to 2012
Available online www.ijpras.com International Journal of Pharmaceutical Research & Allied Sciences, 2016, 5(2):183-189 Research Article ISSN : 2277-3657 CODEN(USA) : IJPRPM The Epidemiological findings
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Summary Volume 13, Issue 1 February, 2014 Tuberculosis in Yakima County The rate of active tuberculosis (TB) in Yakima County has declined by about two-thirds over the past
More informationTuberculosis Procedure ICPr016. Table of Contents
Tuberculosis Procedure ICPr016 Table of Contents Tuberculosis Procedure ICPr016... 1 What is Tuberculosis?... 2 Any required definitions/explanations... 2 NHFT... 2 Tuberculosis (TB)... 3 Latent TB...
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationAnnual surveillance report 2015
Annual surveillance report 215 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,
More informationTUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report
TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION 2000 Tuberculosis Control In the WHO Western Pacific Region 2002 Report World Health Organization Office for the Western Pacific Region iii TUBERCULOSIS
More informationPredicting outcomes and drug resistance with standardised treatment of active tuberculosis
Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationGUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF NOVEMBER 2004] PART I. GROUPED BY AGENCY/ORGANIZATION
GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF NOVEMBER 2004] PART I. GROUPED BY AGENCY/ORGANIZATION Agency/Organization Name of the Guide/Statement Available at World Health Organization 1
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More informationTuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases
Tuberculosis - clinical forms Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases 1 TB DISEASE Primary Post-primary (Secondary) Common primary forms Primary complex Tuberculosis of the intrathoracic
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationInt.J.Curr.Microbiol.App.Sci (2015) 4(9):
ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 744-748 http://www.ijcmas.com Original Research Article Prevalence of HIV-TB Co-Infection and Study of its Epidemiological Variant among Patient s Attending
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Assessment and Follow-Up of TB July, 2018 Page 1 TABLE OF CONTENTS 8.0 ASSESSMENT AND
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More information2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges
Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies
More informationClinical aspects of tuberculosis with directly observed treatment in Mehsana district India
ISPUB.COM The Internet Journal of Health Volume 5 Number 2 Clinical aspects of tuberculosis with directly observed treatment in Mehsana district India P Shailesh, C Ankita, P Asha, P Chaganbhai Citation
More informationI. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %
San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7
More informationCMH Working Paper Series
CMH Working Paper Series Paper No. WG5 : 8 Title Interventions to reduce tuberculosis mortality and transmission in low and middle-income countries: effectiveness, cost-effectiveness, and constraints to
More informationKenya Perspectives. Post-2015 Development Agenda. Tuberculosis
Kenya Perspectives Post-2015 Development Agenda Tuberculosis SPEAKERS Anna Vassall Anna Vassall is Senior Lecturer in Health Economics at the London School of Hygiene and Tropical Medicine. She is a health
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationAuthors Malhotra, S; Zodpey, S P; Chandra, S; Vashist, R P; Satyanaryana, S; Zachariah, R; Harries, A D
MSF Field Research Should Sputum Smear Examination Be Carried Out at the End of the Intensive Phase and End of Treatment in Sputum Smear Negative Pulmonary TB Patients? Authors Malhotra, S; Zodpey, S P;
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationTreatment of Tuberculosis
Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationGlobal Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics
Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More informationThe United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America
The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations
More informationAnnual surveillance report 2016
Annual surveillance report 216 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationTreatment of Tuberculosis
Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Short Communication Awareness of Medical Interns Regarding Recent Guidelines of Revised National Tuberculosis Control
More informationTUBERCULOSIS CONTACT INVESTIGATION
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the criteria used
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationCDC IMMIGRATION REQUIREMENTS:
CDC IMMIGRATION REQUIREMENTS: Technical Instructions for Tuberculosis Screening and Treatment Using Cultures and Directly Observed Therapy October 1, 2009 Table of Contents Preface...i Tuberculosis Screening...1
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationOverview of the Presentation
Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More informationTuberculosis in Chicago 2007
City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationin South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M /j x
MSF Field Research Integrating tuberculosis and HIV care in the primary care setting in South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M Citation DOI Journal Rights
More informationEpidemiology of tuberculosis in Northern Ireland. Annual surveillance report 2007
Epidemiology of tuberculosis in Northern Ireland Annual surveillance report 27 Epidemiology of tuberculosis in Northern Ireland Annual surveillance report 27 Epidemiology of tuberculosis in Northern Ireland:
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationOptimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis
Editorial Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis Sputum smear microscopy has high specificity in tuberculosis-endemic countries, but modest sensitivity that varies
More informationFrances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationStudy of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan
Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationPREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND
JOURNAL OF SCIENCE, Hue University, N 0 61, 2010 PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND Pornnapa
More informationXDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever
More informationActive community surveillance of the impact of different tuberculosis control measures, Tiruvallur, South India,
Int. J. Epidemiol. Advance Access published October 9, 2006 Published by Oxford University Press on behalf of the International Epidemiological Association Ó The Author 2006; all rights reserved. International
More informationTB in Children. Rene De Gama Block 10 Lectures 2012
TB in Children Rene De Gama Block 10 Lectures 2012 Contents Epidemiology Transmission and pathogenesis Diagnosis of TB TB and HIV Management Epidemiology The year 2000 8.3 million new TB cases diagnosed
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationAddressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is
Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is Yale AIDS Program Section of Infectious Diseases Yale University School of Medicine Sheela Shenoi MD MPH September 20, 2012
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationHIV and TB Co-infection. Marsh Gelbart
HIV and TB Co-infection Marsh Gelbart 2010 Learning Outcomes To understand that HIV and TB represent the two biggest threats to world public health and in combination are even more deadly To appreciate
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationAsking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide
Asking the Right Questions A Visual Guide to Tuberculosis Case Management for Nurses Reference Guide The Francis J. Curry National Tuberculosis Center is a joint project of the San Francisco Department
More information